Thomas Foltynie

Active 2002–2026

162
Papers
27,480
Citations
89
h-index
151
i10-index

Citations

Citations per year for Thomas Foltynie1980: 1 citations1984: 1 citations1990: 1 citations1991: 2 citations1999: 1 citations2002: 1 citations2003: 9 citations2004: 10 citations2005: 20 citations2006: 36 citations2007: 36 citations2008: 59 citations2009: 69 citations2010: 65 citations2011: 122 citations2012: 145 citations2013: 215 citations2014: 257 citations2015: 267 citations2016: 287 citations2017: 332 citations2018: 388 citations2019: 1,114 citations2020: 1,363 citations2021: 1,409 citations2022: 1,400 citations2023: 952 citations2024: 1,635 citations2025: 912 citations2026: 46 citations1981–1983: no citations, so these years are not shown1985–1989: no citations, so these years are not shown1992–1998: no citations, so these years are not shown2000–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,874 citing papers, 21.1% of this breakdownUnited Kingdom: 1,593 citing papers, 11.7% of this breakdownChina: 1,196 citing papers, 8.8% of this breakdownGermany: 981 citing papers, 7.2% of this breakdownCanada: 654 citing papers, 4.8% of this breakdownItaly: 624 citing papers, 4.6% of this breakdownFrance: 418 citing papers, 3.1% of this breakdownSpain: 416 citing papers, 3.1% of this breakdownNetherlands: 407 citing papers, 3% of this breakdownAustralia: 375 citing papers, 2.8% of this breakdownSweden: 277 citing papers, 2% of this breakdownIndia: 237 citing papers, 1.7% of this breakdown
0%21.1%Other 26.1%

Fields

  • Medicine68.2%
  • Biochemistry, Genetics and Molecular Biology13.2%
  • Neuroscience13.1%
  • Psychology1.7%
  • Health Professions0.9%
  • Engineering0.7%
  • Other2.2%

Topics

  • Parkinson's Disease Mechanisms and Treatments17.5%
  • Neurological disorders and treatments11.7%
  • Neuroscience and Neural Engineering3%
  • Alzheimer's disease research and treatments2.6%
  • Transcranial Magnetic Stimulation Studies2.3%
  • Nuclear Receptors and Signaling2.2%
  • Other60.7%

Coauthors

All papers

Open in search
  1. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa M. Shulman, Margaret Sutherland, Pentti J. Tienari, Kari Majamaa, Mathias Toft, Ole A. Andreassen, Tushar Bangale, Alexis Brice, Jian Yang, Ziv Gan‐Or, Thomas Gasser, Peter Heutink, Joshua Shulman, Nicholas Wood, David A. Hinds, John Hardy, Huw R Morris, Jacob Gratten, Peter M. Visscher, Robert Graham, Andrew B Singleton, Astrid Adarmes‐Gómez, Miquel Aguilar, Akbota Aitkulova, Vadim Akhmetzhanov, Roy N. Alcalay, Ignacio Álvarez, Victoria Álvarez, Sara Bandrés‐Ciga, Francisco Javier Barrero, Jesús Alberto Bergareche Yarza, Inmaculada Bernal‐Bernal, Kimberley J. Billingsley, Cornelis Blauwendraat, Marta Blazquez, Marta Bonilla‐Toribio, Juan A. Botía, María Teresa Boungiorno, José Brás, Alexis Brice, Kathrin Brockmann, Vivien J. Bubb, Dolores Buiza‐Rueda, Anna Maria Novella Càmara, Fátima Carrillo, Mario Carrión‐Claro, Debora Cerdan, Viorica Chelban, Jordi Clarimón, Carl E Clarke, Yaroslau Compta, Mark Cookson, Jean‐Christophe Corvol, David W. Craig, Fabrice Danjou, Mónica Díez-Fairén, Oriol Dols‐Icardo, J. Duarte, Raquel Durán, Francisco Escamilla‐Sevilla, Valentina Escott‐Price, Mario Ezquerra, Faraz Faghri, Cici Feliz, Manel Fernández, Rubén Fernández‐Santiago, Steven Finkbeiner, Thomas Foltynie, Ziv Gan‐Or, Ciara García and 170 more - The Lancet Neurology 2019 cited by 2,541

  2. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet 2017 cited by 851

  3. Adaptive deep brain stimulation in advanced Parkinson disease

    Authors: , , , , , , , , , , , , - Annals of Neurology 2013 cited by 1,385

  4. Progress towards therapies for disease modification in Parkinson's disease

    Authors: , , , , - The Lancet Neurology 2021 cited by 421

  5. Exenatide and the treatment of patients with Parkinson’s disease

    Authors: , , , , , , , , , , , - Journal of Clinical Investigation 2013 cited by 514

  6. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

    Authors: , - Drug Discovery Today 2016 cited by 370

  7. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nigel Williams, Karen Morrison, Carl E Clarke, Kirsten Harvey, Benjamin M. Jacobs, Alexis Brice, Fabrice Danjou, Suzanne Lesage, Jean‐Christophe Corvol, María Martínez, Claudia Schulte, Kathrin Brockmann, Javier Simón‐Sánchez, Peter Heutink, Patrizia Rizzu, Manu Sharma, Thomas Gasser, Susanne A. Schneider, Mark Cookson, Cornelis Blauwendraat, David W. Craig, Kimberley J. Billingsley, Mary B. Makarious, Derek P. Narendra, Faraz Faghri, J. Raphael Gibbs, Dena Hernández, Kendall Van Keuren‐Jensen, Joshua Shulman, Hirotaka Iwaki, Hampton L. Leonard, Mike A. Nalls, Laurie Robak, José Brás, Rita Guerreiro, Steven Lubbe, Timothy Troycoco, Steven Finkbeiner, Niccolò E. Mencacci, Codrin Lungu, Andrew Singleton, Sonja W. Scholz, Xylena Reed, Ryan J. Uitti, Owen A. Ross, Francis P. Grenn, Anni Moore, Roy N. Alcalay, Zbigniew K. Wszołek, Ziv Gan‐Or, Guy A. Rouleau, Lynne Krohn, Kheireddin Mufti, Jacobus J. van Hilten, Johan Marinus, Astrid D. Adarmes-Gómez, Miquel Aguilar, Ignacio Álvarez, Victoria Álvarez, Francisco Javier Barrero, Jesús Alberto Bergareche Yarza, Inmaculada Bernal‐Bernal, Marta Blázquez Estrada, Marta Bonilla‐Toribio, Juan A. Botía, María Teresa Boungiorno, Dolores Buiza‐Rueda, Ana Cámara, Fátima Carrillo, Mario Carrión‐Claro and 75 more - Nature Communications 2021 cited by 214

  8. European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

    Authors: , , , , , , , , , , , , , , , , , - Movement Disorders 2022 cited by 175

  9. The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

    Authors: , , , - Journal of Parkinson s Disease 2020 cited by 230

  10. Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathrin Brockmann, Janet Brooks, David J. Burn, Elisa Majounie, Gavin Charlesworth, Codrin Lungu, Honglei Chen, Patrick F. Chinnery, Sean Chong, Carl E Clarke, Mark Cookson, Jonathan M. Cooper, Jean‐Christophe Corvol, Carl Counsell, Philippe Damier, Jean‐François Dartigues, Panos Deloukas, Günther Deuschl, David T. Dexter, Karin D. van Dijk, Allissa Dillman, F. Durif, Alexandra Dürr, Sarah Edkins, Jonathan Evans, Thomas Foltynie, Jing Dong, Michelle Gardner, J. Raphael Gibbs, Alison Goate, Emma Gray, Rita Guerreiro, Clare Harris, Jacobus J. van Hilten, Albert Hofman, Albert R. Hollenbeck, Janice L. Holton, Michele Hu, Xuemei Huang, Isabel Wurster, Walter Mätzler, Gavin Hudson, Sarah Hunt, Johanna Huttenlocher, Thomas Illig, Pálmi V. Jónsson, Jean‐Charles Lambert, Cordelia Langford, Andrew J. Lees, Peter Lichtner, Patricia Limousin, Grisel Lopez, Delia Lorenz, Codrin Lungu, Alisdair McNeill, Catriona Moorby, Matthew Moore, Huw R. Morris, Karen Morrison, Valentina Escott‐Price, Ese Mudanohwo, Sean S. O’Sullivan, Justin Pearson, Joel S. Perlmutter, Hjörvar Pétursson, Pierre Pollak, Bart Post, Simon Potter, Bernard Ravina, Tamás Révész and 40 more - Brain 2017 cited by 451

  11. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

    Authors: , , , , , , , , , , - Brain 2009 cited by 958

  12. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

    Authors: , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2013 cited by 692

  13. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

    Authors: , , , , , , , , , , , - JAMA Neurology 2019 cited by 256

  14. The Impact of Type 2 Diabetes in Parkinson's Disease

    Authors: , , , , , , , , , , , , , - Movement Disorders 2022 cited by 128

  15. Insulin resistance and Parkinson’s disease: A new target for disease modification?

    Authors: , - Progress in Neurobiology 2016 cited by 323

  16. Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicholas Wood, Patrick A. Lewis, Sebastian R. Schreglmann, Rita Guerreiro, Ruth C. Lovering, Lea R’Bibo, Claudia Manzoni, Mie Rizig, Mina Ryten, Sebastian Guelfi, Valentina Escott‐Price, Viorica Chelban, Thomas Foltynie, Nigel Williams, Alexis Brice, Fabrice Danjou, Suzanne Lesage, Jean‐Christophe Corvol, María Martínez, Claudia Schulte, Kathrin Brockmann, Javier Simón‐Sánchez, Peter Heutink, Patrizia Rizzu, Manu Sharma, Thomas Gasser, Aude Nicolas, Mark Cookson, Sara Bandrés‐Ciga, Cornelis Blauwendraat, David W. Craig, Faraz Faghri, J. Raphael Gibbs, Dena Hernández, Kendall Van Keuren‐Jensen, Joshua Shulman, Hampton L. Leonard, Mike A. Nalls, Laurie Robak, Steven Lubbe, Steven Finkbeiner, Niccolò E. Mencacci, Codrin Lungu, Andrew Singleton, Sonja W. Scholz, Xylena Reed, Roy N. Alcalay, Ziv Gan‐Or, Guy A. Rouleau, Lynne Krohn, Jacobus J. van Hilten, Johan Marinus, Astrid Adarmes‐Gómez, Miquel Aguilar, Ignacio Álvarez, Victoria Álvarez, Francisco Javier Barrero, Jesús Alberto Bergareche Yarza, Inmaculada Bernal‐Bernal, Marta Blázquez Estrada, Marta Bonilla‐Toribio, Juan A. Botía, María Teresa Boungiorno, Dolores Buiza‐Rueda, Anna Maria Novella Càmara, Fátima Carrillo, Mario Carrión‐Claro, Debora Cerdan, Jordi Clarimón, Yaroslau Compta and 63 more - JAMA Neurology 2021 cited by 203

  17. A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease

    Authors: , , , , , , , , , , , , , - Sensors 2021 cited by 85

  18. Parkinson’s disease dementia: a neural networks perspective

    Authors: , , - Brain 2015 cited by 443

  19. Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

    Authors: , , , , , , , , , , , - Journal of Parkinson s Disease 2014 cited by 295

  20. Bilateral adaptive deep brain stimulation is effective in Parkinson's disease

    Authors: , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2015 cited by 394

  21. Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2020 cited by 173

  22. Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population

    Authors: , , , , , , , , , , , , , , , , , - npj Parkinson s Disease 2023 cited by 60

  23. Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease

    Authors: , , , , , , , , , , , , , - NeuroImage 2017 cited by 284

  24. Mild cognitive impairment in Parkinson disease

    Authors: , , , , , , , , , , , , , , , - Neurology 2010 cited by 740